BridgeMD
Study on the feasibility of fluorescence bronchoscopy with bevacizumab-800CW - DEFLECT I
EU CTIS ID: 2024-510793-24-00
What this study is testing
To assess the feasibility of fluorescence molecular imaging with bevacizumab-800CW during bronchoscopy for identification of malignant pulmonary lesions and/or pathological lymph nodes.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Signed informed consent prior to participation in the study.
- Age ≥ 18 years.
- Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule – with or without pathological lymph nodes – which is considered malignant (independent of its primary origin).
- Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.
You likely can't join if
- History of infusion reactions to bevacizumab or other monoclonal antibodies according to the patient’s medical history
- Medical or psychiatric conditions that compromise the patient’s ability to give informed consent.
- Pregnancy or breast feeding. A negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause) on the day of tracer administration.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.